focus -WSS

focus

author：fashion 2025-09-29 21:28:49 - browse：3779

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Vertex non

hotspot

WSS

Vertex non

No plane should take off without an EpiPen onboard

No plane should take off without an EpiPen onboard

Sage hopes for a blockbuster in antidepressant now before FDA

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Scientists inch closer to single

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Lawsuit alleges UnitedHealth Group unit illegally denied claims

What does generative AI mean for health care? We asked experts

Sage hopes for a blockbuster in antidepressant now before FDA

Hollywood unions extend contract negotiations for actors

Sage hopes for a blockbuster in antidepressant now before FDA

In age of alternative facts, a scholarly course on calling out crap

Physician groups backed by private equity giant lobby on mergers

Hepatitis C has a cure — but many Americans still lack access to it

Wildfire pollution widens asthma inequities on Long Island

leisure time

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Sage hopes for a blockbuster in antidepressant now before FDA

‘Oppenheimer’ and the risks of AI in health care

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

National panel will explore requiring free Covid tests

hotspot

leisure time

focus

explore